Roivant Sciences (ROIV) Cost of Revenue (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Cost of Revenue came in at $965000.0 in Q4 2025, up 36.69% YoY from $706000.0 in Q4 2024, and up 769.37% on a QoQ basis from $111000.0 in Q3 2025.
Roivant Sciences (ROIV) Cost of Revenue (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Cost of Revenue data on file, last reported at $965000.0 in Q4 2025.
- Quarterly Cost of Revenue rose 36.69% year-over-year to $965000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (down 24.26% YoY) and the FY2026 annual result came in at $1.3 million, up 41.05% from the prior year.
- Cost of Revenue climbed to $965000.0 in Q4 2025, from $111000.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $9.0 million in Q4 2022 to a low of $111000.0 in Q3 2025.
- A 5-year average of $2.5 million and a median of $965000.0 in 2025 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2021 — Cost of Revenue soared 1143.71% — and 2024, when it slumped 94.95%.
- Tracing ROIV's Cost of Revenue over 5 years: stood at $8.5 million in 2021, then advanced by 5.24% to $9.0 million in 2022, then tumbled by 84.33% to $1.4 million in 2023, then plunged by 49.68% to $706000.0 in 2024, then surged by 36.69% to $965000.0 in 2025.
- The last three Cost of Revenue figures came in at $965000.0 (Q4 2025), $111000.0 (Q3 2025), and $154000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 284,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 284,000.00 |
| Jun 30, 2026 | 284,000.00 |
| Dec 31, 2025 | 965,000.00 |
| Dec 31, 2025 | 965,000.00 |
| Sep 30, 2025 | 111,000.00 |
| Sep 30, 2025 | 111,000.00 |
| Jun 30, 2025 | 154,000.00 |
| Jun 30, 2025 | 154,000.00 |
| Dec 31, 2024 | 706,000.00 |
| Dec 31, 2024 | 706,000.00 |
| Sep 30, 2024 | 234,000.00 |
| Sep 30, 2024 | 234,000.00 |
| Jun 30, 2024 | 213,000.00 |
| Jun 30, 2024 | 213,000.00 |
| Dec 31, 2023 | 1.40 Mn |
| Dec 31, 2023 | 1.40 Mn |
| Sep 30, 2023 | 223,000.00 |
| Sep 30, 2023 | 223,000.00 |
| Jun 30, 2023 | 4.21 Mn |
| Jun 30, 2023 | 4.21 Mn |